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Summary Ki-67 is a monoclonal antibody which recognises a human nuclear antigen expressed in pro-
liferating cells. The antibody was used to assess proliferation in primary human bladder tumours from 64
patients. Ki-67 index (the number of Ki-67 positive tumour cells divided by the total number of tumour cells %)
was derived from 59 tumours. A wide range of Ki-67 indices were recorded, range 3.0-65.8%, mean 20.2%.
The Ki-67 index correlated with known prognostic factors: T stage (P = 0.002) and histological grade
(P <0.001), early stage disease and more differentiated tumours having lower Ki-67 indices. Patients with
invasive disease (21 patients) had significantly higher Ki-67 indices than those with non-invasive disease
(P = 0.01). Patients with metastatic disease at presentation (four cases) all had a Ki-67 index of >29%. Ki-67
antibody staining is a simple technique for assessing the proliferation fraction than can be performed on a
small amount of tissue taken at routine biopsy without prior injection of thymidine analogues.
Proliferation in human tumour cells has been previously
difficult to measure, but there is evidence that it may be
clinically important. Clinically, bladder tumours can grow
quite rapidly, volume doubling times being estimated to have
a mean value of about 70 days (Steel, 1977), and relapse
when it does occur develops early. Measurement of prolifera-
tion in a series of 350 patients with bladder carcinoma using
flow cytometric analysis of S-phase fraction demonstrated
that high S-phase fraction carries a poor prognosis (Tribukait
et al., 1986). However, apart from technical difficulties in
preparing suitable single tumour cell suspensions, when a
tumour is aneuploid, the determination of the percentage of
the cells in S-phase becomes less precise and sometimes
impossible. Therefore, an alternative method of measuring
proliferation is needed.
Ki-67 is a murine monoclonal antibody raised against the
human Hodgkin's disease-derived cell line L428, and found
to react with a nuclear antigen expressed in proliferating cells
(Gerdes et al., 1983). The nature of the antigen has not been
characterised, but it has been suggested that Ki-67 recognises
a nuclear protein forming part of the DNA replicase complex
(Loke et al., 1987), and has been localised to the nucleolar
cortex and the periphery ofmetaphase chromosomes (Verhei-
jen et al., 1989a and b). A wide range of Ki-67 indices (the
number of Ki-67 positive tumour cells divided by the total
number of tumour cells %) have been reported from a range
of human tumours, the largest range being in Non-Hodgkin's
Lymphoma range 0.5-100% (Hall et al., 1988). The Ki-67
index appears to be related to the biological aggressiveness of
several tumours. This has been demonstrated in Non-
Hodgkin's Lymphoma, lung carcinomas and breast car-
cinoma (Schrape et al., 1987; Gatter et al., 1986; Gerdes et
al., 1986), the more aggressive tumours having the higher
Ki-67 indices. At least two reports have suggested that the
Ki-67 index, although a static measure, may provide a guide
to the proliferation rate of tumours (Hall et al., 1988; Price et
al., 1989).
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This study considers the use of Ki-67 immunostaining in
primary human bladder carcinoma.
Materials and methods
Patients
Sixty-nine bladder biopsies from 64 patients were examined.
All had primary bladder carcinoma, either invasive or non-
invasive disease and biopsies were taken at diagnostic trans-
urethral resection (TUR). The age range of the patients was
45-92 years, mean 73 years. There were 46 male and 18
female patients. The histological subtypes were: transitional
cell carcinoma (63 patients) and carcinosarcoma (one
patient). In general, patient treatment following diagnosis
was either TUR for early non-invasive lesions, or radical
radiotherapy with or without adjuvant chemotherapy for
invasive disease.
Tissue preparation
Tumour biopsies were taken from the primary tumour,
immediately snap frozen in liquid nitrogen and stored at
- 70°C. The remainder of the tumour was fixed in formal
saline and submitted for histological examination.
Grading by histological examination
Histological examinations of 6gm cryostat sections stained
with haematoxylin and eosin were made by one observer
(J.N.). The biopsies were assessed to ensure that adequate
amounts ofwell-preserved tumour was present for cell count-
ing and that the portion of frozen tissue was representative
of the tumour as a whole.
A histological grade was assigned to each tumour using the
grading system proposed by Ash (1940) and based on the
tumour's growth pattern, cytological appearance including
cellular atypia and nuclear pleomorphism, and number of
mitotic figures. Histological grading was performed without
prior knowledge of the clinical stage or Ki-67 proliferation
index of the tumours.
Given that the differentiation of tumours may vary from
area to area (Jewett, 1946) the histological appearance of the
cryostat sections was compared with sections of the formalin-
fixed paraffin-embedded tumour so that any non-representa-
tive frozen biopsies could be identified.
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Immunohistochemistry
6tm cryostat sections were immunohistochemically labelled
with the monoclonal antibody Ki-67 (Dako Ltd.) using an
indirect immunoperoxidase method. Following a 10 min
fixation in acetone, slides were incubated with Ki-67 at a
dilution of 1:10 for 30 min. After a phosphate-buffered saline
(PBS) wash, sections were incubated with peroxidase-
conjugated rabbit anti-mouse immunoglobulins (Dako Ltd.)
at a dilution of 1:20 for 30 min. Following a further PBS
wash, the brown peroxidase stain was visualised using the
chromogenic-substrate diaminobenzidine. Sections were then
counterstained with haematoxylin before mounting. Negative
controls substituted Ki-67 antibody with PBS. Positive con-
trols used were cytocentrifuge preparations of a human
tumour cell line, H x 151, derived from a cervix tumour
(Kelland et al., 1987). All incubations were carried out at
room temperature in a humidified atmosphere.
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Determination ofthe Ki-67proliferation index
All immunostained cryostat sections were examined by two
independent observerg (CB and JN) under light microscopy
using x 800 magnification with an eyepiece graticule. A Ki-67
index (the number of Ki-67 positive tumour cells divided by
the total number of tumour cells %) was derived by counting
at least 1,000 tumour cells in 10 randomly selected fields of
view. The mean of the Ki-67 indices obtained by the two
observers was calculated for each sample. Mean interobserver
count was - 0.41% (SD 6.8) and is demonstrated in Figure 1.
Cell counting was performed without prior knowledge of the
clinical stage or histological grade.
Staging
Tumours were staged according to the 1979 UICC TNM
classification system. Staging investigations included histo-
logical assessment, clinical examination and computer tomo-
graphy (CT) of the pelvis.
Clinical data andstatistical analysis
Clinical follow-up was available in all patients (range 1-30
months, mean 8.5 months).
The Mann-Whitney non-parametric test was used to com-
pare pairs of groups of patients, and the relationship between
the Ki-67 index and histological grade and stage was
evaluated using the Spearman rank correlation.
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Figure 1 Interobserver agreement for Ki-67 indices between the
two observers (CB and JN). The dotted line indicates perfect
agreement. Correlation is 0.88. a, Comparing stage of tumour,
and b, comparing grade of tumour.
Results
Immunohistochemical labelling with Ki-67
Figure 2 shows the typical appearance of a bladder car-
cinoma immunostained with Ki-67 demonstrating the
positive labelling of tumour cell nuclei. The distribution of
positive nuclei varied from specimen to specimen but in the
majority of samples they were diffusely scattered throughout
the section. Intrasection variation on active searching was
always less than 15%. Intrasample variation was always less
than 4%. Cytoplasmic labelling resistant to the blocking of
endogenous peroxidase was rarely seen, but where present
was weak and did not interfere with the identification of
positive nuclei. In 5/69 (7.2%) specimens, taken from
tumours of various grades and stages, repeatedly showed no
labelling with the Ki-67 antibody. This remains unexplained
and these patients were excluded from analysis.
A Ki-67 index was derived in 64 samples from 59 patients.
Ki-67 index ranged from 3.0-65.8% (median 25.3%). In 19
samples (29.7%), sections were cut from either two or three
levels of the biopsy, the variation in Ki-67 index had a mean
value of 3.7 ± 0.5% (range 0.2-10%). In 100% of cases the
histological review of cryostat sections and formalin-fixed
paraffin embedded sections suggested that the derived Ki-67
Figure 2 Ki-67 immunostaining of human bladder biopsy from
a patient with a T3G3 Transitional carcinoma of the bladder. The
Ki-67 labelling is localised in the tumour cell nuclei.
Magnification x 400.
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Figure 3 Relationship between Ki-67 index and T stage.
rs = 0.44, P = 0.002. Each symbol (0) represents the Ki-67
index from an individual biopsy.
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Figure 4 Relationship between Ki-67 index and histological
grade. rs = 0.60, P <0.001. Each symbol (0) represents the
Ki-67 index from an individual biopsy.
index was representative of the biopsy. In three cases (5.1%),
more than one sample was available from the same tumour
and in these cases, Ki-67 index varied by no more than 8%.
Correlation ofKi-67 index with known prognosticfactors
Ki-67 index was correlated with known prognostic factors.
There was a highly significant positive correlation between
Ki-67 index and both T stage (rs = 0.44, P = 0.002) and
histological grade (rs = 0.60, P <0.001). See Figures 3 and 4.
Patients with invasive disease (T2, T3, T4) had higher
Ki-67 indices, (median 26.3%, range 9.6-65.8%) than those
with disease confined to the bladder (Tis, Ta, Tl), (median
12.5%, range 3-60.1%) P<0.001 (Mann-Whitney).
Nodal disease was found in four patients (6.8%), and these
patients had higher Ki-67 indices than those patients with
disease confined to the bladder, although this difference did
not reach significance (P = 0.08).
Distant metastatic disease was present at diagnosis in 4/59
(7%) of patients, all of whom had invasive bladder disease.
In all four patients the Ki-67 index was >29%, although
this was not significantly higher than in those without meta-
static disease (P = 0.21). One patient has developed metas-
tatic disease 15 months after diagnosis and the Ki-67 index
of the original biopsy was the highest recorded (65.8%).
Forty-three specimens were obtained from 40 patients who
presented with non-invasive disease, of which 24 (5.6%) were
recurrences. There was no difference in the Ki-67 index
between the primary and recurrent specimens. No correlation
was found between Ki-67 index and size, site, and number of
tumours, duration of symptoms, time to local recurrence or
age and sex of the patient.
Discussion
Ki-67 immunostaining is a simple technique for assessing
proliferation that can be performed on a small amount of
tissue taken at routine biopsy without injection of thymidine
analogues. Derivation of Ki-67 index was straightforward,
and counting of large number of nuclei reduced sampling
error.
Ki-67 has been shown to bind to cells in active prolifera-
tion and is thought to stain cells in S phase, G2 and most of
GI cells (Gerdes et al., 1983, 1984). The range of immuno-
histochemically derived Ki-67 index derived from the bladder
tumours (3.0-65.8%) is similar to the range in other human
tumours, e.g. breast carcinomas (Barnard et al., 1987). As
Ki-67 immunoreactivity is only detectable on frozen tissue,
without extended follow-up, its clinical importance can only
be inferred from correlation with known prognostic factors.
In bladder carcinoma the Ki-67 index would appear to be
related to the biological aggressiveness of the tumour as
measured by TNM stage and histological grade. This is
similar to the findings in Non-Hodgkin's Lymphoma, lung
and breast carcinoma (Hall et al., 1988; Gatter et al., 1986;
Barnard et al., 1987).
The relationship between proliferative activity and
biological aggressiveness can be explained by two hypotheses.
Firstly, that metastatic potential relies on the acquisition of
specific genetic abnormalities which are acquired randomly
(McMillan & Hart, 1987) and are thus more likely to occur
after repeated cell divisions in a rapidly growing tumour
(Ling et al., 1984). Secondly, that the degree to which a
tumour cell escapes from its regulatory control, is also
reflected in the way in which it escapes from its normal
proliferative control (Tubiana & Courdi, 1989).
If the Ki-67 index of primary bladder carcinoma indicates
those biologically more aggressive tumours, it may be used to
select patients with non-invasive disease who require more
frequent follow-up, or those patients with invasive disease
who are destined to develop metastatic disease and who may
benefit from adjuvant chemotherapy.
Furthermore, there is evidence that the Ki-67 index pro-
vides information about the proliferation rate of human
tumours (Hall et al., 1988; Price et al., 1989). If the Ki-67
index identifies those tumours with a higher per cent of cells
in cycle, it may provide a useful proliferation marker for
stratification in radiotherapy trials where subsets of tumours
able to repopulate rapidly during conventional treatment
may benefit from accelerated fractionation. This question is
at present being addressed in a prospective clinical trial.
We are extremely grateful for the technical assistance given by Mrs
G. O'Byrne and Miss S. Clinton, and the helpful discussions with
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